Changing the way to look at cancer

PITTSBURGH, PA (July 15, 2019) - SpIntellx introduces Spatial Intelligence and Explainable Artificial Intelligence to improve pathology and biopharma research.

Read more…


PITTSBURGH, PA (March 29, 2019) - SpIntellx Announces the Presentation of an Explainable AI Platform (TumorMaprTM) that Provides a Mechanistic Understanding of the Risk Recurrence in Solid Tumors Using Hyperplexed Fluorescence Data Sets at the American Association for Cancer Research (AACR) Annual Meeting on April 1, 2019. Read more…


PITTSBURGH, PA (February 15, 2019) - SpIntellx Awarded Competitive Phase I SBIR Grant from National Science Foundation to Apply Explainable Artificial Intelligence to Breast Pathology. Read more…

Previous News

PITTSBURGH, PA (September 10, 2018) – SpIntellx, Inc., which leverages AI for digital pathology markets, announced the launch of company with the recent closing of a seed financing round led by Newlin Investment Company, an early-stage venture capital firm. Read more…


White Paper

Explainable AI (xAI) is a new approach to AI that can reveal underlying reasons for its results; this is intended to promote safety, reliability, and accountability of machine learning for critical tasks such as pathology diagnosis. HistoMapr is a software platform that provides intelligent xAI guides for pathologists to improve their efficiency and accuracy.